0 XP   0   0   0

Novozymes AS










Financial Health of Novozymes




Comparing to competitors in the Specialty Chemicals industry




  Industry Rankings  


Novozymes AS
Buy, Hold or Sell?

Should you buy, hold or sell Novozymes?

I guess you are interested in Novozymes AS. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

Let's analyse Novozymes

Let's start. I'm going to help you getting a better view of Novozymes AS. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

  1. Company's Financial Health
    A deep dive into the books. How are the numbers doing? Is Novozymes AS even making a profit? Is the company skyrocketing? Or is it sinking like the Titanic. The trend is your friend.
  2. Market Valuation
    Finally, you now have an insight of how Novozymes AS is doing in the market. If the company is worth buying. The latest step is to find out how other investors value Novozymes AS. The closing price on 2022-12-02 was $60.65 per share. Is the company over- or underpriced?
  3. Key Performance Indicators
    A total overlook on how the company is doing. Based on the (trends in) the key performance indicators.
Novozymes AS Daily Candlestick Chart

Summary

Financial Health

Profitability Details
 Compared to previous yearCompared to industry
The company is making a huge profit.
Using its assets, the company is less efficient in making profit.
Using its investors money, the company is less efficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is operating very efficient.
The company is inefficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is just able to pay all its short-term debts.
The company is just not able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is able to pay all its debts by selling its assets.
The company is able to pay all its debts with equity.

1.1. Profitability of Novozymes AS.

1.1. Profitability
1.1.1. Net Profit Margin

Measures how much net profit Novozymes earns for each $1 of revenue.

  • Above 10% is considered healthy but always compare Novozymes to the Specialty Chemicals industry mean.
  • A Net Profit Margin of 18.9% means that $0.19 for each $1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Novozymes AS:

  • The MRQ is 18.9%. The company is making a huge profit. +2
  • The TTM is 19.1%. The company is making a huge profit. +2
Trends
Current periodCompared to+/- 
MRQ18.9%TTM19.1%-0.3%
TTM19.1%YOY21.3%-2.2%
TTM19.1%5Y21.2%-2.1%
5Y21.2%10Y21.2%+0.0%
Compared to industry (Specialty Chemicals)
PeriodCompanyIndustry (mean)+/- 
MRQ18.9%7.2%+11.7%
TTM19.1%6.1%+13.0%
YOY21.3%7.0%+14.3%
5Y21.2%6.2%+15.0%
10Y21.2%6.2%+15.0%
1.1.2. Return on Assets

Shows how efficient Novozymes is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Novozymes to the Specialty Chemicals industry mean.
  • 3.1% Return on Assets means that Novozymes generated $0.03 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Novozymes AS:

  • The MRQ is 3.1%. Using its assets, the company is less efficient in making profit.
  • The TTM is 3.2%. Using its assets, the company is less efficient in making profit.
Trends
Current periodCompared to+/- 
MRQ3.1%TTM3.2%-0.1%
TTM3.2%YOY3.6%-0.4%
TTM3.2%5Y3.8%-0.6%
5Y3.8%10Y3.8%0.0%
Compared to industry (Specialty Chemicals)
PeriodCompanyIndustry (mean)+/- 
MRQ3.1%1.6%+1.5%
TTM3.2%1.5%+1.7%
YOY3.6%1.6%+2.0%
5Y3.8%1.4%+2.4%
10Y3.8%1.4%+2.4%
1.1.3. Return on Equity

Shows how efficient Novozymes is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Novozymes to the Specialty Chemicals industry mean.
  • 6.7% Return on Equity means Novozymes generated $0.07 for each $1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Novozymes AS:

  • The MRQ is 6.7%. Using its investors money, the company is less efficient in making profit.
  • The TTM is 6.7%. Using its investors money, the company is less efficient in making profit.
Trends
Current periodCompared to+/- 
MRQ6.7%TTM6.7%+0.0%
TTM6.7%YOY7.0%-0.3%
TTM6.7%5Y7.0%-0.4%
5Y7.0%10Y7.0%+0.0%
Compared to industry (Specialty Chemicals)
PeriodCompanyIndustry (mean)+/- 
MRQ6.7%3.0%+3.7%
TTM6.7%2.8%+3.9%
YOY7.0%2.9%+4.1%
5Y7.0%2.6%+4.4%
10Y7.0%2.7%+4.3%

1.2. Operating Efficiency of Novozymes AS.

1.2. Operating Efficiency
1.2.1. Operating Margin

Measures how efficient Novozymes is operating .

  • Measures how much profit Novozymes makes for each $1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Novozymes to the Specialty Chemicals industry mean.
  • An Operating Margin of 25.9% means the company generated $0.26  for each $1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Novozymes AS:

  • The MRQ is 25.9%. The company is operating very efficient. +2
  • The TTM is 25.1%. The company is operating very efficient. +2
Trends
Current periodCompared to+/- 
MRQ25.9%TTM25.1%+0.8%
TTM25.1%YOY27.3%-2.2%
TTM25.1%5Y27.2%-2.1%
5Y27.2%10Y27.4%-0.1%
Compared to industry (Specialty Chemicals)
PeriodCompanyIndustry (mean)+/- 
MRQ25.9%8.5%+17.4%
TTM25.1%7.8%+17.3%
YOY27.3%9.2%+18.1%
5Y27.2%7.8%+19.4%
10Y27.4%6.3%+21.1%
1.2.2. Operating Ratio

Measures how efficient Novozymes is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Specialty Chemicals industry mean).
  • An Operation Ratio of 1.19 means that the operating costs are $1.19 for each $1 in net sales.

Let's take a look of the Operating Ratio trends of Novozymes AS:

  • The MRQ is 1.186. The company is inefficient in keeping operating costs low. -1
  • The TTM is 1.190. The company is inefficient in keeping operating costs low. -1
Trends
Current periodCompared to+/- 
MRQ1.186TTM1.190-0.004
TTM1.190YOY1.166+0.024
TTM1.1905Y1.131+0.059
5Y1.13110Y1.132-0.001
Compared to industry (Specialty Chemicals)
PeriodCompanyIndustry (mean)+/- 
MRQ1.1861.607-0.421
TTM1.1901.549-0.359
YOY1.1661.431-0.265
5Y1.1311.369-0.238
10Y1.1321.142-0.010

1.3. Liquidity of Novozymes AS.

1.3. Liquidity
1.3.1. Current Ratio

Measures if Novozymes is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Specialty Chemicals industry mean).
  • A Current Ratio of 1.20 means the company has $1.20 in assets for each $1 in short-term debts.

Let's take a look of the Current Ratio trends of Novozymes AS:

  • The MRQ is 1.195. The company is just able to pay all its short-term debts.
  • The TTM is 1.351. The company is just able to pay all its short-term debts.
Trends
Current periodCompared to+/- 
MRQ1.195TTM1.351-0.155
TTM1.351YOY1.505-0.155
TTM1.3515Y1.380-0.029
5Y1.38010Y1.406-0.027
Compared to industry (Specialty Chemicals)
PeriodCompanyIndustry (mean)+/- 
MRQ1.1951.794-0.599
TTM1.3511.730-0.379
YOY1.5051.743-0.238
5Y1.3801.672-0.292
10Y1.4061.487-0.081
1.3.2. Quick Ratio

Measures if Novozymes is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Novozymes to the Specialty Chemicals industry mean.
  • A Quick Ratio of 0.57 means the company can pay off $0.57 for each $1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Novozymes AS:

  • The MRQ is 0.570. The company is just not able to pay all its short-term debts with the most liquid assets. -1
  • The TTM is 0.658. The company is just not able to pay all its short-term debts with the most liquid assets. -1
Trends
Current periodCompared to+/- 
MRQ0.570TTM0.658-0.088
TTM0.658YOY0.732-0.074
TTM0.6585Y0.651+0.007
5Y0.65110Y0.667-0.016
Compared to industry (Specialty Chemicals)
PeriodCompanyIndustry (mean)+/- 
MRQ0.5700.839-0.269
TTM0.6580.834-0.176
YOY0.7320.864-0.132
5Y0.6510.811-0.160
10Y0.6670.803-0.136

1.4. Solvency of Novozymes AS.

1.3. Liquidity
1.4.1. Debt to Asset Ratio

Measures how much % of Novozymes assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Novozymes to Specialty Chemicals industry mean.
  • A Debt to Asset Ratio of 0.53 means that Novozymes assets are financed with 52.8% credit (debt) and the remaining percentage (100% - 52.8%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of Novozymes AS:

  • The MRQ is 0.528. The company is able to pay all its debts by selling its assets. +1
  • The TTM is 0.511. The company is able to pay all its debts by selling its assets. +1
Trends
Current periodCompared to+/- 
MRQ0.528TTM0.511+0.018
TTM0.511YOY0.478+0.033
TTM0.5115Y0.461+0.050
5Y0.46110Y0.453+0.008
Compared to industry (Specialty Chemicals)
PeriodCompanyIndustry (mean)+/- 
MRQ0.5280.442+0.086
TTM0.5110.425+0.086
YOY0.4780.434+0.044
5Y0.4610.429+0.032
10Y0.4530.430+0.023
1.4.2. Debt to Equity Ratio

Measures if Novozymes is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Novozymes to the Specialty Chemicals industry mean.
  • A Debt to Equity ratio of 115.7% means that company has $1.16 debt for each $1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Novozymes AS:

  • The MRQ is 1.157. The company is able to pay all its debts with equity. +1
  • The TTM is 1.077. The company is able to pay all its debts with equity. +1
Trends
Current periodCompared to+/- 
MRQ1.157TTM1.077+0.080
TTM1.077YOY0.920+0.157
TTM1.0775Y0.871+0.206
5Y0.87110Y0.844+0.026
Compared to industry (Specialty Chemicals)
PeriodCompanyIndustry (mean)+/- 
MRQ1.1570.799+0.358
TTM1.0770.757+0.320
YOY0.9200.775+0.145
5Y0.8710.789+0.082
10Y0.8440.810+0.034

2. Market Valuation of Novozymes AS

2. Earnings Per Share
2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every $1 in earnings Novozymes generates.

  • Above 15 is considered overpriced but always compare Novozymes to the Specialty Chemicals industry mean.
  • A PE ratio of 144.79 means the investor is paying $144.79 for every $1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Novozymes AS:

  • The EOD is 146.287. Seems overpriced? -1
  • The MRQ is 144.791. Seems overpriced? -1
  • The TTM is 181.321. Seems overpriced? -1
Trends
Current periodCompared to+/- 
EOD146.287MRQ144.791+1.495
MRQ144.791TTM181.321-36.529
TTM181.321YOY168.705+12.615
TTM181.3215Y177.829+3.492
5Y177.82910Y160.420+17.409
Compared to industry (Specialty Chemicals)
PeriodCompanyIndustry (mean)+/- 
EOD146.28747.495+98.792
MRQ144.79149.507+95.284
TTM181.32162.325+118.996
YOY168.70562.396+106.309
5Y177.82961.867+115.962
10Y160.42051.163+109.257
2.2. Price Earnings to Growth Ratio

Measures the predicted future growth of Novozymes.

  • Lower is better.
  • A PEG ratio of 1 means the market price of the stock and the expected future earnings are on par.

Let's take a look of the Price Earnings to Growth Ratio trends of Novozymes AS:

  • The MRQ is -5,684.283. Very Bad. -2
  • The TTM is -721.508. Very Bad. -2
Trends
Current periodCompared to+/- 
MRQ-5,684.283TTM-721.508-4,962.775
TTM-721.508YOY-345.666-375.842
TTM-721.5085Y-645.464-76.043
5Y-645.46410Y-601.852-43.613
Compared to industry (Specialty Chemicals)
PeriodCompanyIndustry (mean)+/- 
MRQ-5,684.2830.271-5,684.554
TTM-721.5080.046-721.554
YOY-345.6660.308-345.974
5Y-645.4640.022-645.486
10Y-601.8520.029-601.881

2. Book Value per Share
2.3. Price to Book Ratio

Measures if the stock price of Novozymes is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Specialty Chemicals industry mean).
  • A PB ratio of 9.38 means the investor is paying $9.38 for each $1 in book value.

Let's take a look of the Price to Book Ratio trends of Novozymes AS:

  • The EOD is 9.473. Seems overpriced? -1
  • The MRQ is 9.376. Seems overpriced? -1
  • The TTM is 11.437. Seems overpriced? -1
Trends
Current periodCompared to+/- 
EOD9.473MRQ9.376+0.097
MRQ9.376TTM11.437-2.061
TTM11.437YOY11.674-0.237
TTM11.4375Y9.678+1.759
5Y9.67810Y8.815+0.863
Compared to industry (Specialty Chemicals)
PeriodCompanyIndustry (mean)+/- 
EOD9.4731.959+7.514
MRQ9.3762.102+7.274
TTM11.4372.387+9.050
YOY11.6742.116+9.558
5Y9.6781.934+7.744
10Y8.8151.586+7.229
2. Total Gains per Share

3. Summary

3.1. Key Performance Indicators

The key performance indicators of Novozymes AS compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share--0.4320.202+114%0.032+1246%0.023+1758%0.278+55%
Book Value Growth--0.0650.032+101%0.002+3456%0.003+2484%-0.259+500%
Book Value Per Share--6.4026.132+4%5.563+15%5.891+9%8.952-28%
Book Value Per Share Growth--0.0680.032+110%0.005+1159%0.003+2588%-0.259+484%
Current Ratio--1.1951.351-12%1.505-21%1.380-13%1.406-15%
Debt To Asset Ratio--0.5280.511+3%0.478+11%0.461+15%0.453+17%
Debt To Equity Ratio--1.1571.077+7%0.920+26%0.871+33%0.844+37%
Dividend Per Share--0.0010.584-100%0.558-100%0.576-100%0.908-100%
Dividend Per Share Growth---1518.617-379.404-75%-362.589-76%-244.665-84%-220.444-85%
Eps--0.4150.397+4%0.387+7%0.397+4%0.611-32%
Eps Growth---0.025-0.017-31%0.042-161%-0.355+1292%-0.589+2212%
Gross Profit Margin--1.0001.0000%1.0000%1.0000%1.0000%
Net Profit Margin--0.1890.191-1%0.213-12%0.212-11%0.212-11%
Operating Margin--0.2590.251+3%0.273-5%0.272-5%0.274-5%
Operating Ratio--1.1861.1900%1.166+2%1.131+5%1.132+5%
Pb Ratio9.473+1%9.37611.437-18%11.674-20%9.678-3%8.815+6%
Pe Ratio146.287+1%144.791181.321-20%168.705-14%177.829-19%160.420-10%
Peg Ratio---5684.283-721.508-87%-345.666-94%-645.464-89%-601.852-89%
Price Per Share60.650+1%60.03070.038-14%64.903-8%56.866+6%54.578+10%
Price To Total Gains Ratio140.120+1%138.688102.612+35%224.137-38%121.730+14%107.015+30%
Profit Growth---2.843-1.746-39%3.802-175%-1.889-34%-28.367+898%
Quick Ratio--0.5700.658-13%0.732-22%0.651-13%0.667-15%
Return On Assets--0.0310.032-4%0.036-16%0.038-19%0.038-20%
Return On Equity--0.0670.067+0%0.070-4%0.070-5%0.070-5%
Revenue Growth---0.0200.043-147%0.015-230%0.003-681%-0.264+1230%
Total Gains Per Share--0.4330.787-45%0.590-27%0.599-28%1.186-64%
Total Gains Per Share Growth---0.182-0.110-39%-1.005+452%-0.909+399%-2.295+1161%
Usd Book Value--1769008800.0001697784000.000+4%1548785400.000+14%1634693393.888+8%2479709148.262-29%
Usd Book Value Change Per Share--0.4320.202+114%0.032+1246%0.023+1758%0.278+55%
Usd Book Value Per Share--6.4026.132+4%5.563+15%5.891+9%8.952-28%
Usd Dividend Per Share--0.0010.584-100%0.558-100%0.576-100%0.908-100%
Usd Eps--0.4150.397+4%0.387+7%0.397+4%0.611-32%
Usd Price Per Share60.650+1%60.03070.038-14%64.903-8%56.866+6%54.578+10%
Usd Profit--114554400.000110023200.000+4%107757600.000+6%114480645.840+0%173030630.278-34%
Usd Revenue--606897600.000575320800.000+5%503848200.000+20%539251770.746+13%816638000.590-26%
Usd Total Gains Per Share--0.4330.787-45%0.590-27%0.599-28%1.186-64%
 EOD+2 -3MRQTTM+19 -16YOY+16 -195Y+18 -1710Y+12 -23

3.2. Fundamental Score

Let's check the fundamental score of Novozymes AS based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-15146.287
Price to Book Ratio (EOD)Between0-19.473
Net Profit Margin (MRQ)Greater than00.189
Operating Margin (MRQ)Greater than00.259
Quick Ratio (MRQ)Greater than10.570
Current Ratio (MRQ)Greater than11.195
Debt to Asset Ratio (MRQ)Less than10.528
Debt to Equity Ratio (MRQ)Less than11.157
Return on Equity (MRQ)Greater than0.150.067
Return on Assets (MRQ)Greater than0.050.031
Total4/10 (40.0%)

3.3. Technical Score

Let's check the technical score of Novozymes AS based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
OpenGreater thanClose59.690
Total0/1 (0.0%)



Latest Balance Sheet

Balance Sheet of 2022-06-30. Currency in DKK. All numbers in thousands.

Summary
Total Assets26,495,000
Total Liabilities14,002,000
Total Stockholder Equity12,099,000
 As reported
Total Liabilities 14,002,000
Total Stockholder Equity+ 12,099,000
Total Assets = 26,495,000

Assets

Total Assets26,495,000
Total Current Assets8,560,000
Long-term Assets8,560,000
Total Current Assets
Cash And Cash Equivalents 1,013,000
Short-term Investments 64,000
Net Receivables 4,017,000
Inventory 3,466,000
Total Current Assets  (as reported)8,560,000
Total Current Assets  (calculated)8,560,000
+/-0
Long-term Assets
Property Plant Equipment 11,254,000
Goodwill 2,081,000
Intangible Assets 2,886,000
Other Assets 1,602,000
Long-term Assets  (as reported)17,935,000
Long-term Assets  (calculated)17,823,000
+/- 112,000

Liabilities & Shareholders' Equity

Total Current Liabilities7,162,000
Long-term Liabilities6,840,000
Total Stockholder Equity12,099,000
Total Current Liabilities
Accounts payable 1,597,000
Other Current Liabilities 2,461,000
Total Current Liabilities  (as reported)7,162,000
Total Current Liabilities  (calculated)4,058,000
+/- 3,104,000
Long-term Liabilities
Capital Lease Obligations Min Short Term Debt471,000
Other Liabilities 2,633,000
Long-term Liabilities Other 993,000
Long-term Liabilities  (as reported)6,840,000
Long-term Liabilities  (calculated)4,097,000
+/- 2,743,000
Total Stockholder Equity
Common Stock562,000
Retained Earnings 10,911,000
Other Stockholders Equity 626,000
Total Stockholder Equity (as reported)12,099,000
Total Stockholder Equity (calculated)12,099,000
+/-0
Other
Capital Stock562,000
Common Stock Shares Outstanding 276,303
Net Invested Capital 12,099,000
Net Tangible Assets 7,132,000
Net Working Capital 1,398,000



Balance Sheet

Currency in DKK. All numbers in thousands.

 Trend2022-06-302022-03-312021-12-312021-09-302021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-312016-12-31
> Total Assets 
18,659,000
18,865,000
2,775,046
2,846,401
2,962,575
3,060,459
2,945,596
2,949,799
3,025,095
20,391,000
20,059,000
20,152,000
20,437,000
20,423,000
20,709,000
20,127,000
20,510,000
21,684,000
21,617,000
21,826,000
24,767,000
25,277,000
26,495,000
26,495,00025,277,00024,767,00021,826,00021,617,00021,684,00020,510,00020,127,00020,709,00020,423,00020,437,00020,152,00020,059,00020,391,0003,025,0952,949,7992,945,5963,060,4592,962,5752,846,4012,775,04618,865,00018,659,000
   > Total Current Assets 
6,393,000
6,653,000
944,376
986,475
989,567
1,074,596
1,006,232
1,033,835
1,049,730
6,771,000
6,809,000
6,835,000
7,050,000
7,180,000
6,861,000
6,582,000
6,911,000
7,012,000
7,075,000
7,189,000
7,823,000
8,321,000
8,560,000
8,560,0008,321,0007,823,0007,189,0007,075,0007,012,0006,911,0006,582,0006,861,0007,180,0007,050,0006,835,0006,809,0006,771,0001,049,7301,033,8351,006,2321,074,596989,567986,475944,3766,653,0006,393,000
       Cash And Cash Equivalents 
812,000
754,000
99,416
104,196
101,908
118,244
78,256
90,371
111,039
727,000
910,000
651,000
711,000
926,000
1,024,000
856,000
1,181,000
1,063,000
969,000
863,000
963,000
1,097,000
1,013,000
1,013,0001,097,000963,000863,000969,0001,063,0001,181,000856,0001,024,000926,000711,000651,000910,000727,000111,03990,37178,256118,244101,908104,19699,416754,000812,000
       Short-term Investments 
0
0
0
0
0
0
0
0
0
0
19,000
22,000
15,000
23,000
22,000
78,000
119,000
25,000
28,000
41,000
75,000
97,000
64,000
64,00097,00075,00041,00028,00025,000119,00078,00022,00023,00015,00022,00019,0000000000000
       Net Receivables 
3,089,000
3,377,000
446,220
460,922
468,097
513,765
491,089
504,340
503,440
2,547,000
2,492,000
2,736,000
3,649,000
3,648,000
3,169,000
3,098,000
3,227,000
3,470,000
3,366,000
3,413,000
3,793,000
4,045,000
4,017,000
4,017,0004,045,0003,793,0003,413,0003,366,0003,470,0003,227,0003,098,0003,169,0003,648,0003,649,0002,736,0002,492,0002,547,000503,440504,340491,089513,765468,097460,922446,2203,377,0003,089,000
       Inventory 
2,488,000
2,511,000
393,362
415,366
416,982
434,000
429,859
438,192
433,100
2,808,000
2,780,000
2,801,000
2,613,000
2,560,000
2,624,000
2,528,000
2,361,000
2,443,000
2,701,000
2,860,000
2,992,000
3,082,000
3,466,000
3,466,0003,082,0002,992,0002,860,0002,701,0002,443,0002,361,0002,528,0002,624,0002,560,0002,613,0002,801,0002,780,0002,808,000433,100438,192429,859434,000416,982415,366393,3622,511,0002,488,000
       Other Current Assets 
4,000
11,000
5,378
5,990
2,580
8,588
7,029
932
2,150
0
0
22,000
77,000
46,000
44,000
100,000
142,000
36,000
39,000
53,000
75,000
97,000
64,000
64,00097,00075,00053,00039,00036,000142,000100,00044,00046,00077,00022,000002,1509327,0298,5882,5805,9905,37811,0004,000
   > Long-term Assets 
0
0
0
0
0
0
0
0
0
13,620,000
13,250,000
13,317,000
13,387,000
13,243,000
13,848,000
13,545,000
13,599,000
14,672,000
14,542,000
14,637,000
16,944,000
16,956,000
17,935,000
17,935,00016,956,00016,944,00014,637,00014,542,00014,672,00013,599,00013,545,00013,848,00013,243,00013,387,00013,317,00013,250,00013,620,000000000000
       Property Plant Equipment 
8,641,000
8,663,000
1,307,160
1,349,980
1,439,283
1,467,310
1,446,088
1,444,388
1,489,434
1,558,543
10,232,000
10,321,000
10,212,000
10,103,000
9,952,000
9,717,000
9,612,000
9,736,000
9,681,000
9,755,000
10,185,000
10,436,000
11,254,000
11,254,00010,436,00010,185,0009,755,0009,681,0009,736,0009,612,0009,717,0009,952,00010,103,00010,212,00010,321,00010,232,0001,558,5431,489,4341,444,3881,446,0881,467,3101,439,2831,349,9801,307,1608,663,0008,641,000
       Goodwill 
1,159,000
1,163,000
173,940
176,077
178,661
179,842
170,257
167,078
166,790
1,093,000
967,000
971,000
965,000
963,000
1,120,000
1,106,000
1,098,000
1,537,000
1,493,000
1,506,000
2,020,000
2,049,000
2,081,000
2,081,0002,049,0002,020,0001,506,0001,493,0001,537,0001,098,0001,106,0001,120,000963,000965,000971,000967,0001,093,000166,790167,078170,257179,842178,661176,077173,9401,163,0001,159,000
       Long Term Investments 
224,000
210,000
31,346
22,069
14,190
16,019
13,121
12,577
9,522
0
0
0
0
0
0
0
0
0
0
0
0
0
0
000000000000009,52212,57713,12116,01914,19022,06931,346210,000224,000
       Intangible Assets 
1,578,000
1,533,000
225,108
221,003
213,490
205,605
187,126
170,339
160,339
1,011,000
1,005,000
971,000
961,000
937,000
1,548,000
1,510,000
1,456,000
2,172,000
2,080,000
2,038,000
3,004,000
2,923,000
2,886,000
2,886,0002,923,0003,004,0002,038,0002,080,0002,172,0001,456,0001,510,0001,548,000937,000961,000971,0001,005,0001,011,000160,339170,339187,126205,605213,490221,003225,1081,533,0001,578,000
       Long-term Assets Other 
0
0
0
0
0
0
0
0
0
13,620,000
13,250,000
13,317,000
13,387,000
13,243,000
0
0
0
0
0
0
0
0
0
00000000013,243,00013,387,00013,317,00013,250,00013,620,000000000000
> Total Liabilities 
6,914,000
7,911,000
1,134,604
1,154,040
1,145,815
1,370,535
1,271,145
1,248,273
1,268,430
9,463,000
9,037,000
8,948,000
8,957,000
9,659,000
9,893,000
9,316,000
9,266,000
10,902,000
10,703,000
10,248,000
12,561,000
13,594,000
14,002,000
14,002,00013,594,00012,561,00010,248,00010,703,00010,902,0009,266,0009,316,0009,893,0009,659,0008,957,0008,948,0009,037,0009,463,0001,268,4301,248,2731,271,1451,370,5351,145,8151,154,0401,134,6047,911,0006,914,000
   > Total Current Liabilities 
3,562,000
4,504,000
635,833
665,689
738,023
831,668
780,213
794,553
848,538
5,560,000
5,353,000
5,307,000
4,735,000
4,696,000
4,800,000
4,283,000
4,161,000
5,050,000
4,930,000
4,413,000
5,673,000
6,937,000
7,162,000
7,162,0006,937,0005,673,0004,413,0004,930,0005,050,0004,161,0004,283,0004,800,0004,696,0004,735,0005,307,0005,353,0005,560,000848,538794,553780,213831,668738,023665,689635,8334,504,0003,562,000
       Short-term Debt 
1,803,000
2,618,000
382,452
99,310
156,570
213,697
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
00000000000000000213,697156,57099,310382,4522,618,0001,803,000
       Short Long Term Debt 
1,803,000
2,618,000
382,452
99,310
156,570
213,697
222,271
175,153
274,757
2,103,000
1,851,000
1,551,000
0
1,616,000
1,695,000
1,431,000
0
0
0
0
0
0
0
00000001,431,0001,695,0001,616,00001,551,0001,851,0002,103,000274,757175,153222,271213,697156,57099,310382,4522,618,0001,803,000
       Accounts payable 
1,194,000
1,167,000
174,247
187,742
216,231
204,944
185,877
195,494
217,779
1,111,000
1,097,000
1,040,000
1,117,000
1,078,000
1,112,000
992,000
1,100,000
1,163,000
1,144,000
1,162,000
1,490,000
1,440,000
1,597,000
1,597,0001,440,0001,490,0001,162,0001,144,0001,163,0001,100,000992,0001,112,0001,078,0001,117,0001,040,0001,097,0001,111,000217,779195,494185,877204,944216,231187,742174,2471,167,0001,194,000
       Other Current Liabilities 
1,543,000
2,432,000
338,506
378,637
252,350
413,027
372,065
423,906
244,963
0
0
0
1,327,000
1,848,000
1,842,000
1,721,000
1,236,000
1,716,000
1,772,000
1,770,000
1,347,000
2,384,000
2,461,000
2,461,0002,384,0001,347,0001,770,0001,772,0001,716,0001,236,0001,721,0001,842,0001,848,0001,327,000000244,963423,906372,065413,027252,350378,637338,5062,432,0001,543,000
   > Long-term Liabilities 
0
0
0
0
0
0
0
0
0
3,903,000
3,684,000
3,641,000
4,222,000
4,963,000
5,093,000
5,033,000
5,105,000
5,852,000
5,773,000
5,835,000
6,888,000
6,657,000
6,840,000
6,840,0006,657,0006,888,0005,835,0005,773,0005,852,0005,105,0005,033,0005,093,0004,963,0004,222,0003,641,0003,684,0003,903,000000000000
       Capital Lease Obligations 
0
0
0
0
0
0
0
0
0
691,000
663,000
647,000
616,000
593,000
580,000
542,000
522,000
507,000
549,000
533,000
482,000
468,000
471,000
471,000468,000482,000533,000549,000507,000522,000542,000580,000593,000616,000647,000663,000691,000000000000
       Long-term Liabilities Other 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
146,000
560,000
567,000
587,000
543,000
214,000
993,000
993,000214,000543,000587,000567,000560,000146,0000000000000000000
> Total Stockholder Equity
11,732,000
10,940,000
1,638,445
1,690,312
1,814,664
1,687,613
1,672,420
1,699,508
1,754,669
10,914,000
11,010,000
11,192,000
11,468,000
10,752,000
10,804,000
10,800,000
11,233,000
10,770,000
10,903,000
11,566,000
11,827,000
11,297,000
12,099,000
12,099,00011,297,00011,827,00011,566,00010,903,00010,770,00011,233,00010,800,00010,804,00010,752,00011,468,00011,192,00011,010,00010,914,0001,754,6691,699,5081,672,4201,687,6131,814,6641,690,3121,638,44510,940,00011,732,000
   Common Stock
620,000
610,000
93,731
96,157
98,360
100,738
92,782
92,235
91,227
87,420
582,000
582,000
582,000
570,000
570,000
570,000
570,000
570,000
564,000
564,000
564,000
564,000
562,000
562,000564,000564,000564,000564,000570,000570,000570,000570,000570,000582,000582,000582,00087,42091,22792,23592,782100,73898,36096,15793,731610,000620,000
   Retained Earnings 
10,483,000
9,698,000
1,525,507
1,613,229
1,751,294
1,651,446
1,605,098
1,643,453
1,680,643
10,265,000
10,469,000
10,437,000
10,810,000
10,116,000
10,339,000
10,596,000
11,263,000
10,575,000
10,761,000
11,260,000
11,303,000
10,483,000
10,911,000
10,911,00010,483,00011,303,00011,260,00010,761,00010,575,00011,263,00010,596,00010,339,00010,116,00010,810,00010,437,00010,469,00010,265,0001,680,6431,643,4531,605,0981,651,4461,751,2941,613,2291,525,5079,698,00010,483,000
   Capital Surplus 00000000000000000000000
   Treasury Stock00000000000000000000000
   Other Stockholders Equity 
629,000
632,000
19,207
-19,074
-34,990
-64,572
-25,460
-36,180
-17,201
10,064
-41,000
173,000
76,000
66,000
-105,000
-366,000
-600,000
-375,000
-422,000
-258,000
-40,000
250,000
626,000
626,000250,000-40,000-258,000-422,000-375,000-600,000-366,000-105,00066,00076,000173,000-41,00010,064-17,201-36,180-25,460-64,572-34,990-19,07419,207632,000629,000



Balance Sheet

Currency in DKK. All numbers in thousands.




Cash Flow

Currency in DKK. All numbers in thousands.




Income Statement

Currency in DKK. All numbers in thousands.


Latest Income Statement (annual, 2021-12-31)

Gross Profit (+$)
totalRevenue14,951,000
Cost of Revenue-6,328,000
Gross Profit8,623,0008,623,000
 
Operating Income (+$)
Gross Profit8,623,000
Operating Expense-11,066,000
Operating Income3,885,000-2,443,000
 
Operating Expense (+$)
Research Development2,009,000
Selling General Administrative2,795,000
Selling And Marketing Expenses-
Operating Expense11,066,0004,804,000
 
Net Interest Income (+$)
Interest Income18,000
Interest Expense-102,000
Net Interest Income-104,000-84,000
 
Pretax Income (+$)
Operating Income3,885,000
Net Interest Income-104,000
Other Non-Operating Income Expenses-
Income Before Tax (EBT)3,924,0003,885,000
EBIT - interestExpense = 3,838,000
3,925,000
3,248,000
Interest Expense102,000
Earnings Before Interest and Taxes (ebit)3,940,0004,026,000
Earnings Before Interest and Taxes (ebitda)5,442,000
 
After tax Income (+$)
Income Before Tax3,924,000
Tax Provision-779,000
Net Income From Continuing Ops3,145,0003,145,000
Net Income3,146,000
Net Income Applicable To Common Shares3,146,000
 
Non-recurring Events
Discontinued Operations-
Extraordinary Items-
Effect of Accounting Charges-
Other Items-
Non Recurring-
Other Operating Expenses-66,000
Total Other Income/Expenses Net-104,000
 

Comments

Join the conversation.

Leave a comment

Stay informed with my latest content.

Subscribe to my newsletter and receive an email as soon as I add content to PenkeTrading.com.


By clicking Register, you agree to the General Terms and Conditions.
Penke's Market Notifications
BIKE.XETRA
now

I found you a Overbought RSI (Relative Strength Index) on the daily chart of BIKE.XETRA.

BIKE.XETRA Daily Candlestick Chart
GTK.XETRA
now

I found you a Oversold RSI (Relative Strength Index) on the daily chart of GTK.XETRA.

GTK.XETRA Daily Candlestick Chart
BSL.XETRA
1 minute ago

I found you a Overbought RSI (Relative Strength Index) on the daily chart of BSL.XETRA.

BSL.XETRA Daily Candlestick Chart
UIM1.XETRA
3 minutes ago

I found you a Golden Cross on the daily chart of UIM1.XETRA.

UIM1.XETRA Daily Candlestick Chart
PGN.XETRA
5 minutes ago

I found you a STOCH Bearish Reversal Divergence on the daily chart of PGN.XETRA.

PGN.XETRA Daily Candlestick Chart
LHA.XETRA
5 minutes ago

I found you a Overbought RSI (Relative Strength Index) on the daily chart of LHA.XETRA.

LHA.XETRA Daily Candlestick Chart
SC06.XETRA
9 minutes ago

I found you a Overbought RSI (Relative Strength Index) on the daily chart of SC06.XETRA.

SC06.XETRA Daily Candlestick Chart
BNN.XETRA
10 minutes ago

I found you a Overbought RSI (Relative Strength Index) on the daily chart of BNN.XETRA.

BNN.XETRA Daily Candlestick Chart
NTG.XETRA
16 minutes ago

I found you a STOCH Bearish Reversal Divergence on the daily chart of NTG.XETRA.

NTG.XETRA Daily Candlestick Chart
JUN3.XETRA
16 minutes ago

I found you a Overbought RSI (Relative Strength Index) on the daily chart of JUN3.XETRA.

JUN3.XETRA Daily Candlestick Chart
FEV.XETRA
19 minutes ago

I found you a Golden Cross on the daily chart of FEV.XETRA.

FEV.XETRA Daily Candlestick Chart
EUN2.XETRA
23 minutes ago

I found you a Golden Cross on the daily chart of EUN2.XETRA.

EUN2.XETRA Daily Candlestick Chart
DBPD.XETRA
23 minutes ago

I found you a Death Cross on the daily chart of DBPD.XETRA.

DBPD.XETRA Daily Candlestick Chart
V50A.XETRA
24 minutes ago

I found you a Golden Cross on the daily chart of V50A.XETRA.

V50A.XETRA Daily Candlestick Chart
ETDD.XETRA
25 minutes ago

I found you a Golden Cross on the daily chart of ETDD.XETRA.

ETDD.XETRA Daily Candlestick Chart
CEC.XETRA
27 minutes ago

I found you a Overbought RSI (Relative Strength Index) on the daily chart of CEC.XETRA.

CEC.XETRA Daily Candlestick Chart
XMLC.XETRA
28 minutes ago

I found you a Golden Cross on the daily chart of XMLC.XETRA.

XMLC.XETRA Daily Candlestick Chart
E4C.XETRA
29 minutes ago

I found you a Golden Cross on the daily chart of E4C.XETRA.

E4C.XETRA Daily Candlestick Chart
TULV.TO
29 minutes ago

I found you a Golden Cross on the daily chart of TULV.TO.

TULV.TO Daily Candlestick Chart
ZAL.XETRA
29 minutes ago

I found you a STOCH Bearish Reversal Divergence on the daily chart of ZAL.XETRA.

ZAL.XETRA Daily Candlestick Chart
LOTA.V
29 minutes ago

I found you a STOCH Bearish Hidden Divergence on the daily chart of LOTA.V.

LOTA.V Daily Candlestick Chart
SPTE.LSE
31 minutes ago

I found you a Oversold RSI (Relative Strength Index) on the daily chart of SPTE.LSE.

SPTE.LSE Daily Candlestick Chart
SHP1.LSE
31 minutes ago

I found you a Overbought RSI (Relative Strength Index) on the daily chart of SHP1.LSE.

SHP1.LSE Daily Candlestick Chart
PLTS.LSE
31 minutes ago

I found you a Death Cross on the daily chart of PLTS.LSE.

PLTS.LSE Daily Candlestick Chart